February 2025

New drugs and collaborative care may be key to overcoming trial closures, weak guidelines, and inefficiencies.

This CAR T-cell therapy has revolutionized the management of high-risk and relapsed or refractory disease.

Pharmacists play a crucial role in medication management for these complex patients.

The drug solidifies its place as a first-line treatment option in AML.

BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.

Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.

Relapsed treatment has evolved with CAR T, bispecific antibodies, and immunotherapies.

Treatment selection includes patient factors, cost, adverse effects, and drug interactions.

Second-line and later treatment options for small cell lung cancer are limited.

DLL3 is an emerging therapeutic target in small cell lung cancer and other neuroendocrine carcinomas, with 1 FDA-approved therapy and several others under investigation.

Black women have higher rates of triple-negative breast cancer (TNBC) incidence and mortality than the general US population. Despite this, they are underrepresented in TNBC clinical trials.

The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.

The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.